

Clovis Oncology, Inc.
Form 4
March 31, 2014

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
ATWOOD BRIAN G

(Last) (First) (Middle)

C/O VERSANT VENTURES, 3000
SAND HILL ROAD, BLDG 4,
SUITE 210

(Street)

MENLO PARK, CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Clovis Oncology, Inc. [CLVS]

3. Date of Earliest Transaction
(Month/Day/Year)
03/27/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V Amount (D) Price			
Common Stock	03/27/2014		J ⁽¹⁾	12,213 A \$ 0	13,355	I	See footnote ⁽¹⁾
Common Stock					809,733	I	See footnote ⁽²⁾
Common Stock					5,100	I	See footnote ⁽³⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form

SEC 1474 (9-02)

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Following Reporting Transaction (Instr. 6)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ATWOOD BRIAN G C/O VERSANT VENTURES 3000 SAND HILL ROAD, BLDG 4, SUITE 210 MENLO PARK, CA 94025		X		

Signatures

/s/ Erle T. Mast,
attorney-in-fact

03/31/2014

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The shares were distributed by (i) Versant Ventures IV, LLC ("Versant IV LLC"), the general partner of Versant Venture Capital IV, L.P. ("Versant IV"), (following a distribution of shares from Versant IV to Versant IV LLC) and (ii) Versant Side Fund IV, L.P. ("Versant Side") to the Atwood-Edminster Trust dated 4/2/2000 (the "Trust") in respect of membership interests in Versant IV LLC and limited partnership interests in Versant Side held by the Trust, and, following such distributions, such shares are held directly by the Trust. Brian G. Atwood (the "Reporting Person") is a trustee and a named beneficiary of the Trust. Pursuant to General Instruction 4(b)(iv) to Form 4, all of the shares held by the Trust are reported herein, and the Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

(1) The shares are held by Versant IV. In his capacity as a managing member of Versant IV LLC, which is the general partner of Versant IV, the Reporting Person shares voting and investment authority over the shares held by the Versant IV and may be deemed to beneficially own the shares. Pursuant to General Instruction 4(b)(iv) to Form 4, all of the shares held by Versant IV are reported herein, and the Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

(3)

Edgar Filing: Clovis Oncology, Inc. - Form 4

The shares are held by Versant Side. In his capacity as a managing member of Versant IV LLC, which is the general partner of Versant Side, the Reporting Person shares voting and investment authority over the shares held by the Versant Side and may be deemed to beneficially own the shares. Pursuant to General Instruction 4(b)(iv) to Form 4, all of the shares held by Versant Side are reported herein, and the Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Remarks:

Exhibit List

Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.